Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

Some share price falls are warnings.

Others can be opportunities hiding in plain sight.

That is why I think Cochlear Ltd (ASX: COH) shares deserve a closer look after their heavy decline. The ASX 200 healthcare stock has been sold down sharply, and confidence in the business is clearly weaker than it was before.

But for long-term investors, I think this could be one of the more interesting buying opportunities on the ASX today.

A world leader in a specialised market

Cochlear is not just another healthcare company.

It is a global leader in implantable hearing solutions, with products that can make a life-changing difference for people with moderate to profound hearing loss.

That gives the business a very different profile from many ASX shares.

Cochlear is not relying on discretionary spending, commodity prices, or housing turnover. It is exposed to a large healthcare need that should keep growing as populations age, diagnoses improve, and access to treatment expands.

Hearing loss is a major global issue, and many people who could benefit from treatment still do not receive it. That creates a long runway for companies with trusted technology, clinical relationships, and global distribution.

I think Cochlear has all three.

Why the fall interests me

The market has become much less willing to pay a premium for Cochlear shares.

There are reasons for that. Investors have questioned growth, margins, competition, and whether the company can keep delivering the level of performance that once justified a much higher valuation.

Those concerns should not be ignored.

But the valuation now looks far more interesting. According to CommSec consensus forecasts, Cochlear shares are trading on an estimated FY27 P/E ratio of 18 times.

For a global healthcare leader with a long runway in hearing solutions, I think that looks attractive.

Cochlear still needs to execute well, keep innovating, and protect its position in a competitive healthcare market. But I think the sell-off may have pushed the share price into more appealing territory for patient investors.

A business worth backing for the next decade

The phrase “once-in-a-decade opportunity” should not be used lightly.

Cochlear shares could fall further. Healthcare funding can be complicated, competition can intensify, and expectations may take time to rebuild.

But I do think the current weakness is unusual for a business of this calibre.

High-quality healthcare companies with global leadership positions do not often trade at depressed prices. When they do, I think investors should at least ask whether the market is being too focused on recent disappointment.

For me, the key question is whether Cochlear’s long-term opportunity has been permanently damaged.

I do not think it has.

The world will still need better hearing solutions. More people will still need diagnosis and treatment. Healthcare systems will still value proven technology that can improve patient outcomes.

If Cochlear can keep investing in product development, supporting clinicians, and expanding access, I think the business can recover and grow over the next decade.

Foolish Takeaway

Cochlear shares are out of favour, and that is exactly why they look interesting.

The market is no longer treating the ASX 200 stock like an untouchable healthcare compounder. That creates discomfort, but it may also create opportunity.

I would not expect a quick or smooth rebound. Confidence can take time to return after a major sell-off.

But for investors willing to think in years rather than months, I think Cochlear could be a rare chance to buy a world-class ASX 200 healthcare stock while expectations are unusually low.

The post Could this fallen ASX 200 stock be a once-in-a-decade opportunity? appeared first on The Motley Fool Australia.

More reading

• 4 ASX 200 shares I’d buy with $5,000 this week
• 4 ASX 200 shares tipped to climb 75% to 126% higher
• 3 ASX shares down over 60% that could be bargain buys
• Are these 2 battered ASX healthcare shares too cheap to ignore?
• $10,000 invested in Cochlear shares in July is now worth…

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.